Blood Collection News
-
Showcase
ALung Announces Commercial Development of its Breakthrough Next Generation Artificial Lung
PITTSBURGH–(BUSINESS WIRE)– April 4, 2020 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent initiation of commercial development of its next generation artificial lung, which expands the Company’s focus on highly efficient gas ...
-
ATMP Sterility Testing
Stem cell therapy is a groundbreaking field in the pharmaceutical industry, offering powerful tools for treating severe diseases such as cancer. The genetic manipulations involved in this process, however, necessitate stringent regulations to ensure sterility and safety. In 2017, the Food and Drug Administration (FDA) took significant steps towards regulating stem cell therapy, marking a pivotal ...
-
Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facilitate NALFIA Development
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has recently announced a series of new Anti-Small Molecule Label Antibodies to facilitate the development of nucleic acid lateral flow immunoassay (NALFIA). These antibodies can specifically bind to small molecule labels and offer customers multiple choices, including Anti Digoxin monoclonal ...
-
Creative Proteomics Introduces Innovative Absolute Quantification (AQUA) Service for Precise Protein Quantification Analysis
Creative Proteomics, a leading global provider of proteomics services, is proud to announce the launch of its innovative Absolute Quantification (AQUA) service, offering scientists a highly accurate solution for protein quantification analysis. This groundbreaking service will play a crucial role in life science research, drug development, and clinical diagnostics. Absolute Quantification (AQUA) ...
-
How Technology, Early Diagnoses Can Help Turn the Tide on Prostate Cancer Prognosis
Dr. Ali Tinazli's post at the Forbes magazine about "How Technology, Early Diagnoses Can Help Turn The Tide On Prostate Cancer Prognosis" There has never been more hope or promise in the global effort to eradicate cancer. Confidence in finding lifesaving cures is at an all-time high among medical researchers who work tirelessly for a solution. Astounding ...
-
History of Health Technologies and Meaningful Change in the Era of Health 4.0
Dr. Ali Tinazli's post at the Forbes magazine about "History Of Health Technologies And Meaningful Change In The Era Of Health 4.0" The medicine in ancient Egypt is some of the oldest in history. Although rudimentary, it was already highly personalized and with exclusive access. During the Renaissance—one of the most remarkable ages of humankind—medicine ...
-
Why Knowledge Is Power In The Treatment Of Obesity
Dr. Ali Tinazli is the CEO of lifespin.health and has 15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP). Obesity rates continue to climb alongside a $254.9 billion global weight loss products and services market. Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 ...
-
Circulating Tumor Cell detection by Menarini Group’s CELLSEARCH System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at asymptomatic precursor stages Menarini Silicon Biosystems, a pioneer of liquid biopsy ...
-
Longenesis and Dante Genomics Partner to Make Personalised Medicine More Accessible Across Europe
Biotech and genomics companies Longenesis and Dante Genomics launch more personalised genomic services to more than 10,000 people across the Baltics and Italy, thus expanding and bridging the reach of valuable health insight delivery to patients across Europe. Latvian Biotechnology startup Longenesis has partnered with Dante Genomics, a global company of genomics and precision medicine, to offer ...
By Longenesis
-
VisionGate Focuses on the Importance of Early Detection During Lung Cancer Awareness Month
For many families, November signals the start of the holiday season. It is a special time to gather with loved ones and check-in to make sure everyone is happy and healthy. November is also lung cancer awareness month. VisionGate wants to help you, your family and loved ones learn more about who is at risk, the impact, and the types of lung cancer. Because keeping yourself informed ...
-
ISET technology applied to DLA products from NSCLC patients identified more CTC than other systems
We are enthusiastic to share the results of the research conducted by Dr Tamminga from the University of Groningen. ISET Technology applied to DLA products. This research opens a new interesting way to look at the very rare cancer cells in the patient bloodstream. Rarecells Diagnostics (France), a leading liquid biopsy company, is pleased to announce that the University Medical Center of ...
-
Rarecells, Inc. announces successful Series A funding, reaching $13 Million raised to develop Liquid Biopsy Early Cancer Detection Tests
Rarecells, Inc., an innovative Liquid Biopsy company developing non-invasive tests for early cancer diagnosis, announced today the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million. The funds will support the start of laboratory and clinical operations in the United-States focused on Prostate Cancer and Acute Myeloid Leukemia early detection tests. Rarecells ...
-
Why Innovation in Blood Testing Matters
Why should payers care about clinical laboratory testing? Clinical laboratory testing plays an essential role in the delivery of health care. From early detection and diagnosis of disease to individualized treatment plans based on a person’s unique biology, medical care depends on accurate and timely health data. Seventy percent of medical decisions depend on lab test results, so making ...
-
Babson Diagnostics Welcomes Four New Leaders to Management Team
Babson Diagnostics, a science-first health care technology company, today announced that it continues to grow its management team with the addition of four key leaders. The new team members bring skill sets and experience that will support the commercial launch of its blood testing ecosystem, which reimagines blood testing from collection to sample preparation to analysis, to better meet the ...
-
Lifespin Launches Commercial Access to its Metabolic Profiler Software and Database for Pharma and Biobank Services
Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has launched a new commercial service for the pharmaceutical and biobanking industry to assist companies in key phases of research, development, and manufacturing. Immediate applications of Lifespin’s commercial services, which leverages access to Lifespin’s proprietary ...
-
Now recruiting: Bioinformatics Scientist
Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival? SAGA Diagnostics AB is seeking a talented and highly motivated Bioinformatics Scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive technologies that measure circulating tumor DNA (ctDNA) in ...
-
AIVITA Biomedical Announces Publication of Phase 1 and Phase 2 Trial Results of its COVID-19 Vaccine Candidate
IRVINE, Calif. – AUG. 29, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced the publication of safety and efficacy results from Phase 1 and Phase 2 clinical trials investigating its anti-SARS-CoV-2 vaccine candidate AV-COVID-19 that is made at point-of-care by third-party personnel. The results were published in the article ...
-
Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack involving up to 30,000 patients Bayer drives the development of its FXIa inhibitor, with the goal of offering a ...
By Bayer AG
-
CardioWise™ Receives ISO 13485:2016 Clearance for Design, Development, and Marketing of Software as a Medical Device (SaMD) For the Medical Device Industry
CardioWise, Inc., is pleased to announce that Perry Johnson Registrars, Incorporated has audited the CardioWise Quality Management System (QMS) and determined CardioWise is in conformance with ISO 13485:2016. Perry Johnson Registrars Certificate C2022-02910 was issued July 16, 2022, and represents the first step in the process of obtaining a CE mark and Medical Device Registration for the ...
-
electroCore, Inc. Announces Study of gammaCore Sapphire for the Treatment of Post-COVID Syndrome
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced Mayo Clinic is initiating an investigator-initiated study to assess the efficacy of gammaCore Sapphire non-invasive vagus nerve stimulation (nVNS) in patients with post-COVID syndrome. Post-COVID syndrome, also known as Long COVID, is a collection of symptoms that persist greater than 28 days ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you